Up A Newton MA

Main Menu

  • Conditional Sales Contract
  • Key Performance Indicators
  • Perfect Foresight
  • White-Collar Crime
  • Capital

Up A Newton MA

Header Banner

Up A Newton MA

  • Conditional Sales Contract
  • Key Performance Indicators
  • Perfect Foresight
  • White-Collar Crime
  • Capital
Conditional Sales Contract
Home›Conditional Sales Contract›Helsinn Group and BridgeBio Amend Infigatinib Strategic Compact

Helsinn Group and BridgeBio Amend Infigatinib Strategic Compact

By Mabel McCaw
March 3, 2022
0
0
Helsinn Group, a fully integrated global biopharmaceutical company with a diverse pipeline of oncology assets and a strong track record of commercial execution, and BridgeBio Pharma Inc., a commercial-stage company biopharmaceutical specializing in genetic diseases and cancers, updated their existing strategic collaboration to develop, manufacture and commercialize infigratinib for oncology indications.


Agreement Terms

Under the terms of the amended and restated agreement, Helsinn will obtain an exclusive license to commercialize infigratinib in the United States and will be responsible for the development, manufacturing and commercialization of infigratinib in oncology indications worldwide , excluding achondroplasia or any other skeletal dysplasia and excluding mainland China. , Hong Kong and Macau.

BridgeBio will be eligible to receive regulatory and commercial milestone payments as well as tiered royalties on Helsinn’s adjusted net sales. BridgeBio will retain all development, manufacturing and commercialization rights to infigratinib in skeletal dysplasia, including achondroplasia.

In 2021, Helsinn and BridgeBio secured accelerated approval for TRUSELTIQ (infigratinib) from the United States Food and drug administration ( FDA ) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receiver 2 (FGFR2) fusion or other rearrangement detected by an FDA-cleared test. Additionally, both parties have received conditional approval from Health Canada and tentative approval from the Therapeutics Goods Association in Australia for TRUSELTIQ (infigratinib) for the treatment of adults with previously treated locally advanced or metastatic cholangiocarcinoma, not resectable with an FGFR2 fusion or other rearrangement. Continued approval in the United States, Canada and Australia for this indication may depend on confirmatory trials.

Infigratinib is not approved by the FDA, Health Canada, or Therapeutics Goods Association for any other indication in the United States, Canada, and Australia, nor is it approved for use by any other health authority.


Management Comments

Giorgio Calderari, CEO of Helsinn Group, said: “We are delighted to obtain the exclusive license to commercialize infigratinib in the United States. This perfectly complements our recently announced Fully Integrated Targeted Therapy (FITT) strategy and will utilize our unique capabilities and expertise to advance products through development. and cancer patients around the world. BridgeBio is a great partner, and we look forward to continuing our relationship with them through our non-exclusive collaborative framework to provide co-development and co-commercialization opportunities for precision oncology preclinical programs.

“We are expanding our partnership with Helsinn so that even more patients with FGFR-induced cancers can ultimately access infigratinib. Targeted execution means reducing the scope of our internal activity. We will continue to advance high-quality programs in our pipeline, while enabling Helsinn to develop and commercialize infigratinib in cancer indications for patients in need,” said Neil Kumar, Ph.D. , founder and CEO of BridgeBio.

Related posts:

  1. Fremont City Council Approves Two-Year Renewal of BID, Division of City Administrator Role | Government and politics
  2. DeepMarkit Announces Increase in Offer Size, Transaction Update and Engagement of Meadowbank Strategic Partners
  3. Live news from December 16: ECB and BoE take action to tighten policy, France bans non-essential UK travel on Covid, Brazil to avoid IMF office in Brasilia next year
  4. CITY OF PEOSTA, IOWA COUNCIL PROCEDURES | Legal Notice
Tagsunited states

Recent Posts

  • Boston University will open a new robotics lab to
  • Think of yourself as a business rather than an employee
  • Directors should take note of recent updates to Irish company law
  • Gifts and flowers are fine, but apologies also work
  • Ambitious district agenda, shining example of cooperative federalism: Jitendra Singh | India News

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • August 2019
  • July 2019
  • June 2019
  • May 2019

Categories

  • Capital
  • Conditional Sales Contract
  • Key Performance Indicators
  • Perfect Foresight
  • White-Collar Crime
  • Terms and Conditions
  • Privacy Policy